CJC-1295 without DAC + Ipamorelin

The CJC-1295 without DAC + Ipamorelin-blend is a pre-mixed combination vial in which two growth hormone secretagogues (release-stimulating molecules) are combined in a fixed 1:1 ratio: CJC-1295 without DAC (Mod GRF 1-29), a GHRH analogue (analog of growth hormone-releasing hormone), and Ipamorelin, a selective ghrelin receptor agonist. Both peptides act on the pituitary axis via different signaling pathways and are often studied together in laboratory research. This product is intended exclusively for scientific research.

What is in this blend?

The vial contains both peptides in a 1:1 ratio, pre-combined so that they are available in a single solution after reconstitution. Two concentrations are available: 5 mg + 5 mg and 10 mg + 10 mg per vial.

• CJC-1295 without DAC (Mod GRF 1-29) is a modified fragment of 29 amino acids of GHRH. Four amino acid substitutions (at positions 2, 8, 15 and 27) make the molecule more resistant to enzymatic degradation than the unmodified GRF(1-29). In research models, it is studied for its binding to the GHRH receptor on the pituitary gland.
• Ipamorelin is a selective pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that acts on the ghrelin or growth hormone secretagogue receptor (GHS-R). In research, it is known for its selectivity towards related secretagogues.

Rationale of the combination in research

The two components target different receptors and signaling pathways. Mod GRF 1-29 binds to the GHRH receptor, while Ipamorelin activates the ghrelin receptor. In preclinical studies, this pairing is used to investigate how simultaneous activation of both pathways affects the pulsatile release of endogenous growth hormone from the pituitary gland. This combination of a GHRH analog and a ghrelin receptor agonist is considered a classic model in the literature for studying synergy between the two release pathways and the subsequent IGF-1 axis.

Specifications

CJC-1295 without DAC (Mod GRF 1-29)

Ipamorelin

Shape, handling and storage

Supplied as freeze-dried (lyophilized) white powder in a sealed vial. Store the unopened vial in a cool, dark place; for prolonged storage, storage at −20 °C is common in research settings. After reconstitution with a suitable solvent, store the vial refrigerated (2–8 °C) and avoid exposure to light. Handle the material exclusively with suitable laboratory equipment and in accordance with applicable safety regulations.

Purity and lab results

Both peptides are offered with a controlled purity of ≥ 99%. Analysis certificates and corresponding lab results are available on our lab results page.

Frequently Asked Questions

What does “without DAC” mean? DAC (Drug Affinity Complex) is an addition that extends the circulation time of CJC-1295 in models. In the variant without DAC, this addition is missing, causing the profile to be closer to that of the unprocessed GRF(1-29) fragment. Those looking for the long-lasting variant will find it as CJC-1295 with DAC.

Why are these two offered together? Because they act via different receptors, they are often studied as a pair in research. A similar setup with a GHRH analogue and a ghrelin receptor agonist is the Tesamorelin + Ipamorelin-blend.

How is the powder reconstituted? Reconstitution in research setups is typically performed using bacteriostatic water, which is slowly added against the vial wall. It is not shaken; the powder dissolves slowly into a clear solution.

Want to know more? Read our guide: HGH peptides explained: GHRH analogs, GHRPs, and the difference from real growth hormone.

Intended exclusively for laboratory and research purposes. Not for human or animal consumption, or for medical, diagnostic, therapeutic, or cosmetic use. The buyer is 18+ and confirms the research context. Not a medicine.